Patents by Inventor Elias J. Anaissie

Elias J. Anaissie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7220726
    Abstract: An antifungal composition suitable for parenteral administration to a mammal includes an amount of pimaricin or an antifungal derivative thereof that is effective to inhibit the growth of a fungal infection in a mammal; a pharmaceutically acceptable dipolar aprotic solvent; and a pharmaceutically acceptable aqueous secondary solvent. The composition can be used in methods of preventing or treating a systemic fungal infection in a mammal. The composition can be prepared by dissolving pimaricin or an antifungal derivative thereof in the pharmaceutically acceptable dipolar aprotic solvent; adding to the solution a pharmaceutically acceptable aqueous secondary solvent; and in a preferred method, by subsequently lypohilizing the composition, whereby a dry, shelf-stable composition is produced. This dry composition can be reconstituted into an aqueous solution suitable for parenteral administration.
    Type: Grant
    Filed: May 15, 2003
    Date of Patent: May 22, 2007
    Assignee: Board of Regents, The University of Texas System
    Inventors: Borje S. Andersson, Elias J. Anaissie
  • Patent number: 7153838
    Abstract: An antifungal composition suitable for parenteral administration to a mammal includes an amount of pimaricin or an antifungal derivative thereof that is effective to inhibit the growth of a fungal infection in a mammal; a pharmaceutically acceptable dipolar aprotic solvent; and a pharmaceutically acceptable aqueous secondary solvent. The composition can be used in methods of preventing or treating a systemic fungal infection in a mammal. The composition can be prepared by dissolving pimaricin or an antifungal derivative thereof in the pharmaceutically acceptable dipolar aprotic solvent; adding to the solution a pharmaceutically acceptable aqueous secondary solvent; and in a preferred method, by subsequently lypohilizing the composition, whereby a dry, shelf-stable composition is produced. This dry composition can be reconstituted into an aqueous solution suitable for parenteral administration.
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: December 26, 2006
    Assignee: Board of Regents, the University of Texas System
    Inventors: Borje S. Andersson, Elias J. Anaissie
  • Publication number: 20040037907
    Abstract: An antifungal composition suitable for parenteral administration to a mammal includes an amount of pimaricin or an antifungal derivative thereof that is effective to inhibit the growth of a fungal infection in a mammal; a pharmaceutically acceptable dipolar aprotic solvent; and a pharmaceutically acceptable aqueous secondary solvent. The composition can be used in methods of preventing or treating a systemic fungal infection in a mammal. The composition can be prepared by dissolving pimaricin or an antifungal derivative thereof in the pharmaceutically acceptable dipolar aprotic solvent; adding to the solution a pharmaceutically acceptable aqueous secondary solvent; and in a preferred method, by subsequently lypohilizing the composition, whereby a dry, shelf-stable composition is produced. This dry composition can be reconstituted into an aqueous solution suitable for parenteral administration.
    Type: Application
    Filed: May 15, 2003
    Publication date: February 26, 2004
    Inventors: Borje S. Andersson, Elias J. Anaissie
  • Patent number: 6045815
    Abstract: An antifungal composition suitable for parenteral administration to a mammal includes an amount of pimaricin or an antifungal derivative thereof that is effective to inhibit the growth of a fungal infection in a mammal; a pharmaceutically acceptable dipolar aprotic solvent; and a pharmaceutically acceptable aqueous secondary solvent. The composition can be used in methods of preventing or treating a systemic fungal infection in a mammal. The composition can be prepared by dissolving pimaricin or an antifungal derivative thereof in the pharmaceutically acceptable dipolar aprotic solvent; adding to the solution a pharmaceutically acceptable aqueous secondary solvent; and in a preferred method, by subsequently lypohilizing the composition, whereby a dry, shelf-stable composition is produced. This dry composition can be reconstituted into an aqueous solution suitable for parenteral administration.
    Type: Grant
    Filed: August 15, 1997
    Date of Patent: April 4, 2000
    Assignee: Board of Regents, The University of Texas System
    Inventors: Borje S. Andersson, Elias J. Anaissie
  • Patent number: 4999199
    Abstract: The present invention involves a pharmaceutical formulation comprising a liposome having a therapeutically effective concentration of an aromatic polyene macrolide antibiotic. The aromatic polyene macrolide antibiotic usable in the practice of the present invention is selected from the group consisting of candicidin, hamycin, aurefungin, ascosin, ayfattin, azacolutin, DJ400-B, trichomycin, levorin, heptamycin, candimycin or perimycin. The most preferred aromatic polyene macrolide antibiotic is candicidin. An important aspect of the present invention is a method for treating disseminated fungal infection in an animal comprising administering to an animal such as a human a pharmaceutical formulation comprising a liposome having a therapeutically effective amount of aromatic polyene macrolide antibiotic as described above.
    Type: Grant
    Filed: November 10, 1988
    Date of Patent: March 12, 1991
    Assignee: Board of Regents, The University of Texas System
    Inventors: Elias J. Anaissie, Georgios Samonis, Hans Krause, Gerald P. Bodey